GOIRC – Gruppo Oncologico Italiano di Ricerca Clinica
GOIRC is a leading organization in the field of clinical oncology research in Italy. Since its foundation, GOIRC has distinguished itself by supporting and promoting clinical research in oncology, facilitating collaboration between research centers and hospitals to improve treatments and the quality of life for cancer patients.
Thanks to its expertise in the field, GOIRC has developed a network of excellence that fosters innovation in clinical research, ensuring high scientific standards and promoting advanced studies for the development of new therapeutic strategies.
Role
GOIRC handles regulatory submissions for the Path for Young study in Italy, coordinates site activation, and aims to recruit 200 patients. Additionally, it supports participating centers to ensure compliance with the protocol, Good Clinical Practice (GCP), and applicable regulations, maintaining high scientific and quality standards.
Members
Musolino Antonino
Professor Antonino Musolino is a renowned physician and clinical researcher dedicated to advancing oncology care and research, particularly in breast cancer, cancer epidemiology, and pharmacogenetics. His work bridges scientific discovery and clinical practice to improve patient outcomes.
He has served as Associate Professor of Medical Oncology at the University of Parma and Head of the Breast Unit at the University Hospital of Parma, integrating research into clinical care. Currently, he leads the Medical Oncology, Breast, and GYN Unit at the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" in Meldola, Italy. Additionally, he is the President of the Italian Oncology Group of Clinical Research (GOIRC), fostering collaboration and innovation in cancer research.
His research focuses on molecular and genetic factors influencing cancer progression and treatment responses, with a strong emphasis on breast cancer. He is particularly interested in pharmacogenetics, which tailors therapies to individual genetic profiles, improving treatment effectiveness.
As a clinician, educator, and researcher, Prof. Musolino is committed to advancing oncology, enhancing patient care, and driving scientific progress through collaboration and innovation.